CelAgace™ OraRinse Solution for Treatment of Candidiasis
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Candidiasis, Oral
In brief
CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.
Key facts
- Study ID
- NCT03250923
- Run by
- CelaCare Technologies, Inc.
- People needed
- 15
- Starts
- 2024-09-01
- Expected to finish
- 2025-05-01
- Last updated by the study team
- 2024-02-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Radiation induced oral mucositis with resulting candidiasis
- Chemotherapy induced oral mucositis with resulting candidiasis
- Oral mucositis due to being immunocompromised with resulting candidiasis
- Stomatitis due to other causes with resulting candidiasis
- Currently have mild to moderate mucositis
You may not qualify if…
- Patient:
- under the age of 18
- pregnant or breastfeeding
- inability to use an oral rinse
- hypersensitivity to Aloe Vera and/or Silver
- whose candida rinse culture was performed greater than 10 days prior to study entry.
- has any sort of removable dental appliance
- with previous or current history of any cancer of the oral cavity
- who received therapy for candidiasis within the past 30 days
- who used antifungal medication in the last 30 days
- who has severe to life threatening oral muositis (Grade III-IV) oral mucositis
- with impaired renal or hepatic function
- receiving high dose chemotherapy and total body irradiation in preparation for Hemopoietic Stem Cell Transplant (HSCT) or Concomitant use of Kepivance® (palifermin or rhKGF)
Where it is running
- Texas A&M University College of Dentistry — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.